» Articles » PMID: 17562875

Neutrophils Efficiently Cross-prime Naive T Cells in Vivo

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 2007 Jun 15
PMID 17562875
Citations 149
Authors
Affiliations
Soon will be listed here.
Abstract

Neutrophils are professional phagocytes that migrate early, in high number, to the infection sites. Our study has analyzed how neutrophils cross-present antigens and influence CD8+ T-cell responses. By using highly purified neutrophils from peritoneal exudates and bone marrow, we have shown that neutrophils cross-present ovalbumin to a CD8+ T-cell hybridoma and to naive CD8+ T cells from OT1 transgenic mice. Cross-presentation by neutrophils was TAP and proteasome dependent and was as efficient as in macrophages. Moreover, it actually occurred earlier than in professional antigen-presenting cells. Peritoneal exudate neutrophils from mice injected intraperitoneally with ovalbumin also cross-presented ovalbumin, proving that neutrophils take up and present exogenous antigens into major histocompatibility complex I (MHC I) molecules in vivo. We then evaluated the in vivo influence of antigen cross-presentation by neutrophils on CD8+ T-cell response using beta2-microglobulin-deficient mice transferred with OT1 CD8+ T cells and injected with ovalbumin-pulsed neutrophils. Four days after neutrophil injection, OT1 cells proliferated and expressed effector functions (IFN-gamma production and cytolysis). They also responded efficiently to a rechallenge with ovalbumin-pulsed dendritic cells in CFA. These data are the first demonstration that neutrophils cross-prime CD8+ T cells in vivo and suggest that they may constitute, together with professional antigen-presenting cells, an attractive target to induce cytotoxic T cells in vaccines.

Citing Articles

Neutrophil Engulfment in Cancer: Friend or Foe?.

Lu T, Li W Cancers (Basel). 2025; 17(3).

PMID: 39941753 PMC: 11816126. DOI: 10.3390/cancers17030384.


Targeting Cancer: Microenvironment and Immunotherapy Innovations.

Padzinska-Pruszynska I, Taciak B, Kiraga L, Smolarska A, Gorczak M, Kucharzewska P Int J Mol Sci. 2025; 25(24.

PMID: 39769334 PMC: 11679359. DOI: 10.3390/ijms252413569.


Tumor Integrin-Targeted Glucose Oxidase Enzyme Promotes ROS-Mediated Cell Death that Combines with Interferon Alpha Therapy for Tumor Control.

Stinson J, Sheen A, Lax B, Yang G, Duhamel L, Santollani L Mol Cancer Ther. 2024; 24(1):118-130.

PMID: 39382078 PMC: 11695183. DOI: 10.1158/1535-7163.MCT-24-0163.


Neutrophil Extracellular Traps in Tumors and Potential Use of Traditional Herbal Medicine Formulations for Its Regulation.

Li X, Hu L, Naeem A, Xiao S, Yang M, Shang H Int J Nanomedicine. 2024; 19:2851-2877.

PMID: 38529365 PMC: 10961241. DOI: 10.2147/IJN.S449181.


Novel peptide-based oncolytic vaccine for enhancement of adaptive antitumor immune response via co-engagement of innate Fcγ and Fcα receptors.

Feola S, Hamdan F, Russo S, Chiaro J, Fusciello M, Feodoroff M J Immunother Cancer. 2024; 12(3).

PMID: 38458776 PMC: 10928783. DOI: 10.1136/jitc-2023-008342.